Shockwave Medical Inc. (SWAV)

30.67
NASDAQ : Health Technology
Prev Close 31.54
Day Low/High 29.00 / 32.43
52 Wk Low/High 24.58 / 68.39
Avg Volume 407.60K
Exchange NASDAQ
Shares Outstanding 28.03M
EPS -1.50
P/E Ratio 9.04
Div & Yield N.A. (N.A)

Latest News

Shockwave Medical Reports Second Quarter 2019 Financial Results

Shockwave Medical Reports Second Quarter 2019 Financial Results

SANTA CLARA, Calif., Aug.

Shockwave Medical To Report Second Quarter 2019 Financial Results On August 5, 2019

Shockwave Medical To Report Second Quarter 2019 Financial Results On August 5, 2019

SANTA CLARA, Calif., July 23, 2019 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc.

Shockwave Medical To Participate In The 39th Annual Canaccord Genuity Global Growth Conference

Shockwave Medical To Participate In The 39th Annual Canaccord Genuity Global Growth Conference

SANTA CLARA, Calif., July 23, 2019 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc.

Baking It In: Cramer's 'Mad Money' Recap (Thursday 5/23/19)

Baking It In: Cramer's 'Mad Money' Recap (Thursday 5/23/19)

Jim Cramer says we need to bake in as much bad news as possible before the market really finds a bottom. There will be more declines ahead.

Cypress Semi, American Airlines: 'Mad Money' Lightning Round

Cypress Semi, American Airlines: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Cypress Semi, American Airlines, The Blackstone Group, United Technologies, ShockWave Medical and more.

Investing's Not a Game: Cramer's 'Mad Money' Recap (Thursday 4/25/19)

Investing's Not a Game: Cramer's 'Mad Money' Recap (Thursday 4/25/19)

Jim Cramer says it's the start CNBC's annual Stock Draft Contest, but he cautions Mad Money viewers that although investing can be fun, it requires discipline and doing your homework.

ShockWave Medical Reaches Analyst Target Price

ShockWave Medical Reaches Analyst Target Price

In recent trading, shares of ShockWave Medical Inc have crossed above the average analyst 12-month target price of $34.00, changing hands for $34.50/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.